Less than 24 hours to go…

It’s the eve of the election, and a lot is at stake for investors. From tech regulation, to taxes and energy policy, there’s a ton riding on the outcome. We’ll follow everything you need to know – including the record money pouring into campaigns, and all the possible outcomes for stocks in the coming days. Plus, our own Meg Tirrell explains why Regeneron’s promising COVID-19 antibody treatment would be in short supply if the FDA approved it today.